Insider Selling: Adlai Nortye (NASDAQ:ANL) Director Sells $159,900.00 in Stock

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Director Ping Ji sold 10,000 shares of the firm’s stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $15.99, for a total value of $159,900.00. Following the completion of the sale, the director owned 121,453 shares in the company, valued at $1,942,033.47. The trade was a 7.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Ping Ji also recently made the following trade(s):

• On Tuesday, September 29th, Ping Ji sold 214 shares of Adlai Nortye stock. The shares were sold at an average price of $15.77, for a total transaction of $3,374.78.
• On Tuesday, September 22nd, Ping Ji sold 5,000 shares of Adlai Nortye stock. The shares were sold at an average price of $16.63, for a total value of $83,150.00.

Adlai Nortye Stock Performance

Shares of NASDAQ:ANL opened at $15.09 on Friday. The company has a 50 day moving average price of $14.34 and a 200 day moving average price of $12.27. Adlai Nortye Ltd. Sponsored ADR has a 1-year low of $0.88 and a 1-year high of $17.25.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Adlai Nortye in a research report on Tuesday, September 8th. Cantor Fitzgerald initiated coverage on shares of Adlai Nortye in a report on Monday, June 22nd. They set an “overweight” rating on the stock. Jefferies Financial Group assumed coverage on shares of Adlai Nortye in a research note on Thursday, September 10th. They issued a “buy” rating and a $31.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Finally, Loop Capital set a $49.00 target price on Adlai Nortye in a research note on Tuesday, September 8th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Adlai Nortye currently has a consensus rating of “Moderate Buy” and an average price target of $29.50.

Institutional Trading of Adlai Nortye

A number of institutional investors have recently added to or reduced their stakes in the business. SmartHarvest Portfolios LLC grew its position in Adlai Nortye by 8.5% in the first quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock worth $113,000 after acquiring an additional 1,279 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Adlai Nortye in the 1st quarter valued at $457,000. Seven Fleet Capital Management LP bought a new stake in Adlai Nortye in the second quarter worth $1,302,000. ADAR1 Capital Management LLC bought a new stake in Adlai Nortye in the first quarter worth $816,000. Finally, Affinity Asset Advisors LLC bought a new stake in shares of Adlai Nortye during the 1st quarter worth about $1,140,000. 35.21% of the stock is currently owned by institutional investors and hedge funds.

About Adlai Nortye

Adlai Nortye Ltd. (NASDAQ: ANL) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research and development programs are centered on immuno-oncology and targeted therapies intended to address unmet medical needs.

Adlai Nortye’s pipeline has included buparlisib, an oral pan-PI3K inhibitor being studied in oncology, as well as AN0025, an investigational EP4 antagonist designed to affect pathways involved in tumor growth and immune response.